Abstract
Objectives: To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice.
Methods: A total number of 263 subjects (189 men, median age 48.1 years) with HIV-1 RNA < 50 copies/mL for ≥ 6 months were switched to RAL (400 mg b.i.d). Reasons for change were toxicity (49.0%), drug interactions (6.1%) or convenience (28.6%) (switch from subcutaneous to oral treatment 22.4%, improvement of posology 3.4%). Patients were followed up to 24 months after switching to RAL. Primary end-points were tolerability and virological failure defined as two consecutive measures of HIV-1 RNA > 50 copies/mL.
Results: After a median of 12.4 months (range 2.8-26.4 months), virological failure was observed in 6 (2.3%) patients (2.2 per 100 person-years [95%CI 0.9-4.6]), while AIDS occurred in 1, drug discontinuation in 4, 3 patients died and 10 were lost to follow-up. The median CD4+ T cell count increased from 460 cells/mm3 to 508.6 cells/mm3 (P < 0.001).
Conclusions: Switching to RAL in clinical practice was mainly driven by toxicity, convenience or interactions, they were well tolerated and secured virologic suppression in the vast majority of patients.
Keywords: Raltegravir, simplification strategy, HIV infection, toxicity, CD4+, T cell, patients, lipid, virological, suppression
Current HIV Research
Title:Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study
Volume: 10 Issue: 8
Author(s): Vicente Estrada, The TORAL Study Group, Manuel Castano, Jorge Carmena, Antonio Antela, Josefa Galindo, Esteban Ribera, Joaquin Portilla, Ferran Segura, Eugenia Negredo, Daniel Podzamczer, Hernando Knobel, Ignacio Santos, Antonio Ocampo, Maria-Jesus Perez-Elias, Jordi Curto, Pompeyo Viciana, Elena Ferrer, Pere Domingo and Esteban Martinez
Affiliation:
Keywords: Raltegravir, simplification strategy, HIV infection, toxicity, CD4+, T cell, patients, lipid, virological, suppression
Abstract: Objectives: To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice.
Methods: A total number of 263 subjects (189 men, median age 48.1 years) with HIV-1 RNA < 50 copies/mL for ≥ 6 months were switched to RAL (400 mg b.i.d). Reasons for change were toxicity (49.0%), drug interactions (6.1%) or convenience (28.6%) (switch from subcutaneous to oral treatment 22.4%, improvement of posology 3.4%). Patients were followed up to 24 months after switching to RAL. Primary end-points were tolerability and virological failure defined as two consecutive measures of HIV-1 RNA > 50 copies/mL.
Results: After a median of 12.4 months (range 2.8-26.4 months), virological failure was observed in 6 (2.3%) patients (2.2 per 100 person-years [95%CI 0.9-4.6]), while AIDS occurred in 1, drug discontinuation in 4, 3 patients died and 10 were lost to follow-up. The median CD4+ T cell count increased from 460 cells/mm3 to 508.6 cells/mm3 (P < 0.001).
Conclusions: Switching to RAL in clinical practice was mainly driven by toxicity, convenience or interactions, they were well tolerated and secured virologic suppression in the vast majority of patients.
Export Options
About this article
Cite this article as:
Estrada Vicente, TORAL Study Group The, Castano Manuel, Carmena Jorge, Antela Antonio, Galindo Josefa, Ribera Esteban, Portilla Joaquin, Segura Ferran, Negredo Eugenia, Podzamczer Daniel, Knobel Hernando, Santos Ignacio, Ocampo Antonio, Perez-Elias Maria-Jesus, Curto Jordi, Viciana Pompeyo, Ferrer Elena, Domingo Pere and Martinez Esteban, Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study, Current HIV Research 2012; 10 (8) . https://dx.doi.org/10.2174/157016212803901428
DOI https://dx.doi.org/10.2174/157016212803901428 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Tyrosine Isomers in Acute and Chronic Diseases Leading to Oxidative Stress - A Review
Current Medicinal Chemistry Editorial [ Hot Topic: Modifying Cardiovascular Risk Factors: Novel Cardiovascular Targets for Treatment by Noninvasive Imaging Techniques (Executive Editors: Aurelio Leone and Luigi Landini) ]
Current Pharmaceutical Design The Lipid-lowering Effects and Associated Mechanisms of Dietary Phytosterol Supplementation
Current Pharmaceutical Design Hypertensive Cardiomyopathy in Asymptomatic Patients: A Neglected Diagnosis
Current Hypertension Reviews Chemistry of Plant Dyes: Applications and Environmental Implications of Dyeing Processes
Current Environmental Engineering Potential Options to Treat Hypertriglyceridaemia
Current Drug Targets Editorial (Hot Topic: Matrix Metalloproteinases: Drug Targets in Cardiovascular Diseases)
Current Drug Targets Insulin and the Brain
Current Diabetes Reviews Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design The Fetal Cardiac Function
Current Cardiology Reviews Left Ventricular Hypertrophy Beyond Hemodynamics: Genetic, Metabolic and Hormonal Factors
Current Hypertension Reviews Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
Current Medicinal Chemistry Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Current Pharmaceutical Design Recent Applications of Triazolopyrimidine-Based Bioactive Compounds in Medicinal and Agrochemical Chemistry
Mini-Reviews in Medicinal Chemistry The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Editorial [Hot topic: Interstitial Lung Disease with Connective Tissue Diseases (Guest Editor: Eric Matteson)]
Current Rheumatology Reviews Retinal Nerve Fiber Layer Thickness is Associated with Episodic Memory Deficit in Mild Cognitive Impairment Patients
Current Alzheimer Research Testing of Compounds in Models of Pulmonary Emphysema
Current Medicinal Chemistry Matricellular Proteins in Myocardial Infarction
Current Cardiology Reviews Averrhoa bilimbi L. leaf Aqueous Extract Modulates both Cardiac Contractility and Frequency in the Guinea-pig Atrium by the Activation of Muscarinic Receptors
Letters in Drug Design & Discovery